Literature DB >> 15769560

Deaths of clients in methadone treatment in Texas: 1994-2002.

Jane Carlisle Maxwell1, Thomas W Pullum, Karen Tannert.   

Abstract

This study analyzes causes of deaths of 766 patients who died while in methadone treatment in Texas between 1994 and 2002. Compared with deaths in the general population of Texas, deaths of clients in methadone treatment were 4.6 times more likely to be from a drug overdose, 3.4 times more likely to be from liver disease, 1.7 times more likely to be from a respiratory disease, 1.5 times more likely to be from a homicide and 1.4 times more likely to be from AIDS, but less likely to be from suicide, motor vehicle accidents, cardiovascular diseases or cancer. Of the clients, 20% died of liver disease, 18% of cardiovascular disease and 14% of drug overdose. An older cohort had been in treatment longer, had more take-homes, were on higher doses and tended to die of chronic diseases. A younger cohort tended to die from traumas, including drug overdose. Time in treatment was 43.3 months; mean daily dose was 77.3mg; number of days/month dosed in the clinic was 13.9. Given these rates, the scope of services should include on-site treatment for other medical conditions and staff should be educated about and counsel about the risk of death for new patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15769560     DOI: 10.1016/j.drugalcdep.2004.09.006

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  8 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates.

Authors:  L J Cohen; E Gertmenian-King; L Kunik; C Weaver; E D London; I Galynker
Journal:  Acta Psychiatr Scand       Date:  2005-08       Impact factor: 6.392

Review 3.  Supervised Injectable Opioid Treatment for the Management of Opioid Dependence.

Authors:  James Bell; Vendula Belackova; Nicholas Lintzeris
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 4.  Pharmacotherapy of dual substance abuse and dependence.

Authors:  George A Kenna; Darci M Nielsen; Patricia Mello; Alison Schiesl; Robert M Swift
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

Review 6.  Pharmacological maintenance treatments of opiate addiction.

Authors:  James Bell
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  The necessity of checking the status and performance of methadone maintenance treatment centers in iran.

Authors:  Mohammad Davood Mohebi
Journal:  Int J High Risk Behav Addict       Date:  2013-03-12

8.  Dynamic changes in prescription opioids from 2006 to 2017 in Texas.

Authors:  Ebuwa O Ighodaro; Kenneth L McCall; Daniel Y Chung; Stephanie D Nichols; Brian J Piper
Journal:  PeerJ       Date:  2019-12-06       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.